Insider · CIK 0001450608
Duncan P Hennes
Files at C (CITIGROUP INC), RNR (RENAISSANCERE HOLDINGS LTD). First filing -, latest -.
In brief
Duncan P Hennes files SEC Form 4 as director at C (CITIGROUP INC), and also at RNR (RENAISSANCERE HOLDINGS LTD). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Duncan P Hennes has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | C CITIGROUP INC | AGrant or award Common Stock | +6 | $131.59 | $854 | 1,693 | 11 d ago |
| Oct 1, 2026 | C CITIGROUP INC | AGrant or award Common Stockindirect: See Footnote | +201 | $131.59 | $26k | 39,649 | 11 d ago |
| Jul 1, 2026 | C CITIGROUP INC | AGrant or award Common Stock | +5 | $142.56 | $762 | 1,687 | Jul 2, 2026 |
| Jul 1, 2026 | C CITIGROUP INC | AGrant or award Common Stockindirect: See Footnote | +165 | $142.56 | $24k | 39,448 | Jul 2, 2026 |
| Apr 1, 2026 | C CITIGROUP INC | AGrant or award Common Stock | +7 | $110.99 | $758 | 1,681 | Apr 2, 2026 |
| Apr 1, 2026 | C CITIGROUP INC | AGrant or award Common Stockindirect: See Footnote | +211 | $110.99 | $23k | 39,283 | Apr 2, 2026 |
| Mar 1, 2026 | RNR RENAISSANCERE HOLDINGS LTD | AGrant or award Common Stock | +578 | $0.00 | $0 | 8,696 | Mar 3, 2026 |
| Jan 2, 2026 | C CITIGROUP INC | AGrant or award Common Stock | +1,263 | $0.00 | $0 | 3,836 | Jan 6, 2026 |
| Jan 2, 2026 | C CITIGROUP INC | AGrant or award Common Stock | +11 | $118.80 | $1,297 | 1,675 | Jan 6, 2026 |
| Jan 2, 2026 | C CITIGROUP INC | AGrant or award Common Stockindirect: See Footnote | +185 | $118.80 | $22k | 39,071 | Jan 6, 2026 |
| Oct 1, 2025 | C CITIGROUP INC | AGrant or award Common Stock | +13 | $102.37 | $1,289 | 2,573 | Oct 3, 2025 |
| Oct 1, 2025 | C CITIGROUP INC | AGrant or award Common Stockindirect: See Footnote | +214 | $102.37 | $22k | 36,714 | Oct 3, 2025 |
| Jul 1, 2025 | C CITIGROUP INC | AGrant or award Common Stock | +14 | $83.53 | $1,195 | 2,561 | Jul 3, 2025 |
| Jul 1, 2025 | C CITIGROUP INC | AGrant or award Common Stockindirect: See Footnote | +243 | $83.53 | $20k | 36,500 | Jul 3, 2025 |
| Apr 1, 2025 | C CITIGROUP INC | AGrant or award Common Stock | +16 | $72.18 | $1,186 | 2,546 | Apr 3, 2025 |
| Apr 1, 2025 | C CITIGROUP INC | AGrant or award Common Stockindirect: See Footnote | +279 | $72.18 | $20k | 36,257 | Apr 3, 2025 |
| Mar 1, 2025 | RNR RENAISSANCERE HOLDINGS LTD | AGrant or award Common Stock | +694 | $0.00 | $0 | 8,118 | Mar 4, 2025 |
| Jan 2, 2025 | C CITIGROUP INC | AGrant or award Common Stock | +2,118 | $0.00 | $0 | 2,530 | Jan 6, 2025 |
| Jan 2, 2025 | C CITIGROUP INC | AGrant or award Common Stockindirect: See Footnote | +24 | $70.83 | $1,680 | 35,719 | Jan 6, 2025 |
| Jan 2, 2025 | C CITIGROUP INC | AGrant or award Common Stockindirect: See Footnote | +259 | $70.83 | $18k | 35,978 | Jan 6, 2025 |
Questions about Duncan P Hennes
Answered from the filings on this page, as of the latest one.
Is Duncan P Hennes buying or selling?
Duncan P Hennes has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Duncan P Hennes's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Duncan P Hennes has 0.
Where does Duncan P Hennes file Form 4?
Duncan P Hennes has filed Form 4 at C (CITIGROUP INC); RNR (RENAISSANCERE HOLDINGS LTD). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.